AngioDynamics, Inc. (ANGO)
15.20
-0.27
(-1.75%)
USD |
NASDAQ |
Sep 04, 16:00
15.18
-0.02
(-0.13%)
After-Hours: 20:00
AngioDynamics Research and Development Expense (Quarterly) : 8.178M for May 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| May 31, 2026 | 8.178M |
| February 28, 2026 | 7.084M |
| November 30, 2025 | 7.768M |
| August 31, 2025 | 6.417M |
| May 31, 2025 | 6.59M |
| February 28, 2025 | 6.913M |
| November 30, 2024 | 6.434M |
| August 31, 2024 | 6.285M |
| May 31, 2024 | 6.724M |
| February 29, 2024 | 8.189M |
| November 30, 2023 | 8.658M |
| August 31, 2023 | 7.941M |
| May 31, 2023 | 7.86M |
| February 28, 2023 | 6.852M |
| November 30, 2022 | 6.838M |
| August 31, 2022 | 8.333M |
| May 31, 2022 | 7.866M |
| February 28, 2022 | 7.28M |
| November 30, 2021 | 8.199M |
| August 31, 2021 | 7.394M |
| May 31, 2021 | 9.104M |
| February 28, 2021 | 8.565M |
| November 30, 2020 | 9.712M |
| August 31, 2020 | 9.009M |
| May 31, 2020 | 7.232M |
| Date | Value |
|---|---|
| February 29, 2020 | 8.395M |
| November 30, 2019 | 7.764M |
| August 31, 2019 | 6.292M |
| May 31, 2019 | 6.892M |
| February 28, 2019 | 6.915M |
| November 30, 2018 | 7.076M |
| August 31, 2018 | 7.374M |
| May 31, 2018 | 6.168M |
| February 28, 2018 | 6.457M |
| November 30, 2017 | 6.107M |
| August 31, 2017 | 6.441M |
| May 31, 2017 | 6.696M |
| February 28, 2017 | 5.951M |
| November 30, 2016 | 5.913M |
| August 31, 2016 | 6.709M |
| May 31, 2016 | 6.937M |
| February 29, 2016 | 5.808M |
| November 30, 2015 | 6.179M |
| August 31, 2015 | 6.202M |
| May 31, 2015 | 7.289M |
| February 28, 2015 | 6.855M |
| November 30, 2014 | 6.069M |
| August 31, 2014 | 6.718M |
| May 31, 2014 | 6.753M |
| February 28, 2014 | 7.045M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Boston Scientific Corp. | 554.00M |
| Penumbra, Inc. | 19.96M |
| Abbott Laboratories | 892.00M |
| Alphatec Holdings, Inc. | 18.17M |
| AtriCure, Inc. | 25.67M |